HedgeChatter

  • Home /
  • Tag Archives

PFE

Pfizer Statement on Today’s Joint Meeting of FDA Advisory Committees

[Business Wire] – Pfizer agrees with the recommendation of the joint meeting of the FDA Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee that the available data do moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]

February 11, 2014 Bystocknews , Comments Off on Pfizer Statement on Today’s Joint Meeting of FDA Advisory Committees read more

FDA panel says data does not support lower heart risk of naproxen

[Reuters] – An advisory panel to the U.S. Food and Drug Administration voted on Tuesday that there is not enough evidence to show conclusively that the painkiller naproxen carries a lower cardiac risk than other popular products. The panel voted 16-9 tha moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who […]

February 11, 2014 Bystocknews , Comments Off on FDA panel says data does not support lower heart risk of naproxen read more

Stock Market News for February 11, 2014

moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]

February 11, 2014 Bystocknews , Comments Off on Stock Market News for February 11, 2014 read more

Pfizer’s BOSULIF® (bosutinib) Receives Conditional Marketing Authorization From The European Commission

[at noodls] – NYSE: PFE US7170811035 NEW YORK–( BUSINESS WIRE)–Pfizer Inc. announced today that the European Commission (EC) has granted conditional marketing authorization for BOSULIF® (bosutinib) in the European … moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]

March 28, 2013 Bystocknews , Comments Off on Pfizer’s BOSULIF® (bosutinib) Receives Conditional Marketing Authorization From The European Commission read more

XELJANZ® (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA)

[Business Wire] – NEW YORK–(BUSINESSWIRE)– Pfizer Inc. (NYSE: PFE) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved XELJANZ ® (tofacitinib citrate) for the treatment of adults … moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]

March 25, 2013 Bystocknews , Comments Off on XELJANZ® (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA) read more

Lpath Granted Key European and U.S. Patents Related to Anti-Cancer Drug Program, ASONEP

[at noodls] – Patents Provide Coverage for Lpath’s Anti-S1P Antibody in the Treatment of a Wide Variety of Hyperproliferative Disorders, Including Cancer SAN DIEGO, CA — (MARKETWIRE) — 03/22/13 — Lpath, Inc. (NASDAQ: … moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]

March 22, 2013 Bystocknews , Comments Off on Lpath Granted Key European and U.S. Patents Related to Anti-Cancer Drug Program, ASONEP read more

UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease

[at noodls] – NEW YORK and CARMIEL, Israel, March 18, 2013 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that the Brazilian National Health Surveillance … moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]

March 18, 2013 Bystocknews , Comments Off on UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease read more

ELIQUIS® (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation

[Business Wire] – PRINCETON, N.J. & NEW YORK–(BUSINESSWIRE)– Bristol-Myers Squibb (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved ELIQUIS® … moreView todays social media effects on PFEView the latest stocks trending across Twitter. Click to view dashboardSee who Pfizer is hiring next, click here to view […]

December 26, 2012 Bystocknews , Comments Off on ELIQUIS® (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation read more